FDA Approves Teva's Migraine Drug Ajovy
2018年9月15日 - 9:14AM
Dow Jones News
By Maria Armental
Teva Pharmaceutical Industries Ltd.'s (TEVA, TEVA.TV) migraine
drug Ajovy has been approved for sale in the U.S., the latest in a
new class of specially targeted drugs.
Ajovy should be available in about two weeks, Teva said, and its
wholesale-acquisition cost--an industry term for the price drug
companies charge wholesalers--will be about $575 for a 225 mg
monthly dose and $1,725 for a 675 mg quarterly dose.
The most common adverse reactions in clinical trials were
injection-site reactions, the company said.
Amgen Inc. and Novartis AG's Aimovig was approved in May with a
list price of $6,900 a year.
Teva, the world's biggest seller of generic drugs, had been
counting on the approval of fremanezumab to boost sales.
"The way we recover is Ajovy," Chief Executive Kåre Schultz said
last month, using the brand name for fremanezumab.
The Israeli drugmaker reported a 14% revenue decline for the
first half of the year, which the company has attributed in part to
continued pricing pressure in its U.S. generics business and
generic competition to multiple-sclerosis drug Copaxone.
Shares, which have outperformed the market with a 21% gain this
year, rose 5% to $24.09 in after-hours trading.
Write to Maria Armental at maria.armental@wsj.com
(END) Dow Jones Newswires
September 14, 2018 19:59 ET (23:59 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 6 2024 まで 7 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
過去 株価チャート
から 7 2023 まで 7 2024
